• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Re: Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.

作者信息

Bahrami Bobak, Hong Thomas, Chang Andrew

机构信息

Sydney Institute of Vision Science, 13/187 Macquarie Street, Sydney, NSW, 2000, Australia.

Save Sight Institute, University of Sydney, Sydney, NSW, Australia.

出版信息

Graefes Arch Clin Exp Ophthalmol. 2017 Jul;255(7):1453-1454. doi: 10.1007/s00417-017-3670-5. Epub 2017 Apr 8.

DOI:10.1007/s00417-017-3670-5
PMID:28391371
Abstract
摘要

相似文献

1
Re: Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.关于：将治疗从贝伐单抗转换为阿柏西普用于持续性糖尿病黄斑水肿的管理。
Graefes Arch Clin Exp Ophthalmol. 2017 Jul;255(7):1453-1454. doi: 10.1007/s00417-017-3670-5. Epub 2017 Apr 8.
2
Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.将治疗方案从贝伐单抗转换为阿柏西普以治疗持续性糖尿病性黄斑水肿。
Graefes Arch Clin Exp Ophthalmol. 2017 Jul;255(7):1451-1452. doi: 10.1007/s00417-017-3669-y. Epub 2017 Apr 7.
3
Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.将治疗方案从贝伐单抗转换为阿柏西普以治疗持续性糖尿病性黄斑水肿。
Graefes Arch Clin Exp Ophthalmol. 2017 Jun;255(6):1133-1140. doi: 10.1007/s00417-017-3624-y. Epub 2017 Feb 25.
4
Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success.阿柏西普治疗既往贝伐单抗治疗无效的糖尿病性黄斑水肿：治疗结果及成功预测因素
Graefes Arch Clin Exp Ophthalmol. 2018 Jan;256(1):83-89. doi: 10.1007/s00417-017-3836-1. Epub 2017 Oct 29.
5
Aflibercept for Diabetic Macular Edema in Eyes Previously Treated With Ranibizumab and/or Bevacizumab May Further Improve Macular Thickness.阿柏西普用于曾接受雷珠单抗和/或贝伐单抗治疗的糖尿病性黄斑水肿眼，可能会进一步改善黄斑厚度。
Ophthalmic Surg Lasers Imaging Retina. 2016 Sep 1;47(9):836-9. doi: 10.3928/23258160-20160901-06.
6
Conversion to Aflibercept After Prior Anti-VEGF Therapy for Persistent Diabetic Macular Edema.既往抗血管内皮生长因子治疗持续性糖尿病黄斑水肿后改用阿柏西普治疗
Am J Ophthalmol. 2016 Aug;168:290-291. doi: 10.1016/j.ajo.2016.05.015. Epub 2016 Jun 4.
7
Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success.阿柏西普治疗既往贝伐单抗治疗无效的糖尿病性黄斑水肿：疗效及成功预测因素
Graefes Arch Clin Exp Ophthalmol. 2018 Jul;256(7):1353-1354. doi: 10.1007/s00417-018-3951-7. Epub 2018 Mar 9.
8
Short-Term Effects of Early Switching to Ranibizumab or Aflibercept in Diabetic Macular Edema Cases With Non-Response to Bevacizumab.在对贝伐单抗无反应的糖尿病性黄斑水肿病例中早期改用雷珠单抗或阿柏西普的短期效果
Ophthalmic Surg Lasers Imaging Retina. 2017 Mar 1;48(3):230-236. doi: 10.3928/23258160-20170301-06.
9
Short-Term Outcomes of Aflibercept Therapy for Diabetic Macular Edema in Patients With Incomplete Response to Ranibizumab and/or Bevacizumab.阿柏西普治疗对雷珠单抗和/或贝伐单抗反应不完全的糖尿病性黄斑水肿患者的短期疗效
Ophthalmic Surg Lasers Imaging Retina. 2015 Oct;46(9):950-4. doi: 10.3928/23258160-20151008-08.
10
Reply to the letter to the editor: Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success.致编辑的信的回复：阿柏西普治疗既往贝伐单抗治疗无效的糖尿病性黄斑水肿：治疗结果及成功预测因素
Graefes Arch Clin Exp Ophthalmol. 2018 Jul;256(7):1355-1356. doi: 10.1007/s00417-018-3952-6. Epub 2018 Mar 10.

本文引用的文献

1
Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.将治疗方案从贝伐单抗转换为阿柏西普以治疗持续性糖尿病性黄斑水肿。
Graefes Arch Clin Exp Ophthalmol. 2017 Jun;255(6):1133-1140. doi: 10.1007/s00417-017-3624-y. Epub 2017 Feb 25.
2
Diabetic macular oedema: pathophysiology, management challenges and treatment resistance.糖尿病性黄斑水肿：病理生理学、管理挑战与治疗抵抗
Diabetologia. 2016 Aug;59(8):1594-608. doi: 10.1007/s00125-016-3974-8. Epub 2016 May 14.
3
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.
阿柏西普、贝伐单抗或雷珠单抗治疗糖尿病性黄斑水肿：一项比较疗效随机临床试验的两年结果。
Ophthalmology. 2016 Jun;123(6):1351-9. doi: 10.1016/j.ophtha.2016.02.022. Epub 2016 Feb 27.
4
Intravitreal aflibercept for diabetic macular edema.玻璃体内注射阿柏西普治疗糖尿病性黄斑水肿。
Ophthalmology. 2014 Nov;121(11):2247-54. doi: 10.1016/j.ophtha.2014.05.006. Epub 2014 Jul 8.
5
Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE.雷珠单抗治疗糖尿病黄斑水肿的长期疗效：两项 III 期临床试验（RISE 和 RIDE）的 36 个月结果。
Ophthalmology. 2013 Oct;120(10):2013-22. doi: 10.1016/j.ophtha.2013.02.034. Epub 2013 May 22.
6
Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial.玻璃体腔内注射贝伐单抗联合或不联合曲安奈德治疗难治性糖尿病性黄斑水肿：一项安慰剂对照的随机临床试验。
Graefes Arch Clin Exp Ophthalmol. 2008 Apr;246(4):483-9. doi: 10.1007/s00417-007-0688-0. Epub 2007 Oct 5.
7
Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group.糖尿病性黄斑水肿的光凝治疗。糖尿病视网膜病变早期治疗研究报告第1号。糖尿病视网膜病变早期治疗研究研究组。
Arch Ophthalmol. 1985 Dec;103(12):1796-806.